78 316

Cited 42 times in

Evaluation of short-term safety and efficacy of HMG-CoA reductase inhibitors in hypercholesterolemic patients with elevated serum alanine transaminase concentrations: PITCH study (PITavastatin versus atorvastatin to evaluate the effect on patients with hypercholesterolemia and mild to moderate hepatic damage)

Authors
Han, KH; Rha, SW; Kang, HJ; Bae, JW; Choi, BJ; Choi, SY; Gwon, HC; Bae, JH; Hong, BK; Choi, DH; Han, KR
Citation
Journal of clinical lipidology, 6(4):340-351, 2012
Journal Title
Journal of clinical lipidology
ISSN
1933-2874
Abstract
BACKGROUND: We evaluated the safety and efficacy of the 3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and pitavastatin in patients with mild-to-moderate increased levels of hepatic enzymes.



METHODS AND RESULTS: In this 12-week, prospective, randomized, open-label, active drug-controlled, and dose-titration study, 189 subjects with elevated low-density lipoprotein cholesterol (≥3.36 mmol/L) and alanine transaminase (ALT; ×1.25≥ and ≤×2.5 ULN; 50-100 IU/L) concentrations, but nonalcoholic and serologically negative for viral hepatitis markers at screening, were randomized to 12 weeks of treatment with pitavastatin 2-4 mg/day (PITA, n = 97) or atorvastatin 10-20 mg/day (ATOR, n = 92). Pitavastatin and atorvastatin equally reduced low-density lipoprotein cholesterol concentrations (-34.6 ± 16.0% and -38.1 ± 16.2%, respectively, P 100 IU/L at weeks 4 and 12, respectively, with one patient in each group excluded because of severe ALT elevation >3× ULN (>120 IU/L) at week 4. The 135 patients with persistently increased ALT concentrations at screening and randomization showed significant reductions in ALT after 12 weeks of treatment with PITA (n = 68, -8.4%) or ATOR (n = 67, -8.9%; P 100 IU/L).



CONCLUSIONS: Conventional doses of pitavastatin and atorvastatin effectively and safely reduce elevated hepatic enzyme concentrations.
MeSH terms
AdultAgedAlanine Transaminase/*bloodCholesterol, LDL/bloodDrug Administration ScheduleFatty Liver/radiographyFemaleHeptanoic Acids/*therapeutic useHumansHydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic useHypercholesterolemia/blood/*drug therapyMaleMiddle AgedPyrroles/*therapeutic useQuinolines/*therapeutic useTriglycerides/blood
DOI
10.1016/j.jacl.2012.01.009
PMID
22836071
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Cardiology
AJOU Authors
최, 병주최, 소연
Full Text Link
Files in This Item:
fulltext not available.txtDownload
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse